R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.
PRMT8 (E2R7O) Rabbit mAb #83283
Filter:
- WB
Supporting Data
REACTIVITY | M |
SENSITIVITY | Endogenous |
MW (kDa) | 45 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- M-Mouse
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
PRMT8 (E2R7O) Rabbit mAb recognizes endogenous levels of total PRMT8 protein. This antibody does not recognize PRMT1.
Species Reactivity:
Mouse
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly323 of human PRMT8 protein.
Background
Arginine methylation is a prevalent PTM found on both nuclear and cytoplasmic proteins. Arginine methylated proteins are involved in many different cellular processes, including transcriptional regulation, signal transduction, RNA metabolism, and DNA damage repair (1-3). Arginine methylation is carried out by the arginine N-methyltransferase (PRMT) family of enzymes that catalyze the transfer of a methyl group from S-adenosylmethionine (AdoMet) to a guanidine nitrogen of arginine (4). There are three different types of arginine methylation: asymmetric dimethylarginine (aDMA, omega-NG,NG-dimethylarginine), where two methyl groups are placed on one of the terminal nitrogen atoms of the guanidine group of arginine; symmetric dimethylarginine (sDMA, omega-NG,NG-dimethylarginine), where one methyl group is placed on each of the two terminal guanidine nitrogens of arginine; and monomethylarginine (MMA, omega-NG-methylarginine), where a single methyl group is placed on one of the terminal nitrogen atoms of arginine. Each of these modifications has potentially different functional consequences. Though all PRMT proteins catalyze the formation of MMA, Type I PRMTs (PRMT1, 3, 4, 6, and 8) add an additional methyl group to produce aDMA, while Type II PRMTs (PRMT5 and 7) produce sDMA. Methylated arginine residues often reside in glycine-arginine rich (GAR) protein domains, such as RGG, RG, and RXR repeats (5). However, PRMT4/CARM1 and PRMT5 methylate arginine residues within proline-glycine-methionine rich (PGM) motifs (6).
PRMT8 is a Type I PRMT closely related to PRMT1 and is expressed primarily in the brain. PRMT8 has a unique N-terminus that is myristoylated, which targets it to the plasma membrane (7). The N-terminal domain also is responsible for PRMT8 activity, and contains two automethylation sites that regulate affinity for AdoMet. (8,9). PRMT8 has been shown to be critical in neural development (10,11). In post-mitotic neurons, PRMT8 provides a protective role against double-stranded DNA breaks that accumulate with aging (12). Overexpression of PRMT8 has been shown to be associated with tau phosphorylation and neuroinflammation (13). PRMT8 is also expressed in stem cells and can control pluripotency and mesodermal fate through the PI3K/Akt/Sox2 axis (14,15).
PRMT8 is a Type I PRMT closely related to PRMT1 and is expressed primarily in the brain. PRMT8 has a unique N-terminus that is myristoylated, which targets it to the plasma membrane (7). The N-terminal domain also is responsible for PRMT8 activity, and contains two automethylation sites that regulate affinity for AdoMet. (8,9). PRMT8 has been shown to be critical in neural development (10,11). In post-mitotic neurons, PRMT8 provides a protective role against double-stranded DNA breaks that accumulate with aging (12). Overexpression of PRMT8 has been shown to be associated with tau phosphorylation and neuroinflammation (13). PRMT8 is also expressed in stem cells and can control pluripotency and mesodermal fate through the PI3K/Akt/Sox2 axis (14,15).
- Bedford, M.T. and Richard, S. (2005) Mol Cell 18, 263-72.
- Pahlich, S. et al. (2006) Biochim Biophys Acta 1764, 1890-903.
- Bedford, M.T. and Clarke, S.G. (2009) Mol Cell 33, 1-13.
- McBride, A.E. and Silver, P.A. (2001) Cell 106, 5-8.
- Gary, J.D. and Clarke, S. (1998) Prog Nucleic Acid Res Mol Biol 61, 65-131.
- Cheng, D. et al. (2007) Mol Cell 25, 71-83.
- Lee, J. et al. (2005) J Biol Chem 280, 32890-6.
- Sayegh, J. et al. (2007) J Biol Chem 282, 36444-53.
- Dillon, M.B. et al. (2013) J Biol Chem 288, 27872-80.
- Lin, Y.L. et al. (2013) PLoS One 8, e55221.
- Simandi, Z. et al. (2015) Stem Cells 33, 726-41.
- Simandi, Z. et al. (2018) J Neurosci 38, 7683-7700.
- Ishii, A. et al. (2022) J Biochem 172, 233-243.
- Solari, C. et al. (2016) Biochem Biophys Res Commun 473, 194-199.
- Jeong, H.C. et al. (2017) Stem Cells 35, 2037-2049.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.